Publications by authors named "Gilles Defer"

Claim this Profile
T
Therapeutic Management During Pregnancy and Relapse Risk in Women With Multiple Sclerosis.
Antoine Gavoille, Fabien Rollot, Romain Casey, Guillaume Mathey, Emmanuelle Le Page, Gilles Defer

JAMA Neurol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of geographical accessibility to specialist and primary care givers on excess mortality of multiple sclerosis patients in France.
Sarah Wilson, Emmanuelle Leray, Floriane Calocer, Fabien Rollot, Mathieu Fauvernier, Gilles Defer

BMC Neurol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Target trial emulation to replicate randomised clinical trials using registry data in multiple sclerosis.
Antoine Gavoille, Mikail Nourredine, Fabien Rollot, Romain Casey, Guillaume Mathey, Gilles Defer

J Neurol Neurosurg Psychiatry· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of Disease-Modifying Therapies in Patients With Late-Onset Multiple Sclerosis.
Camille Robin, Fabien Rollot, Mathilde Lefort, Romain Casey, Sandra Vukusic, Gilles Defer

Neurology· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis.
Antoine Gavoille, Emmanuelle Leray, Romain Marignier, Fabien Rollot, Romain Casey, Gilles Defer

Neurology· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Secondary progression activity monitoring in MS despite an early highly active treatment the SPAM study.
Mikael Cohen, Fabien Rollot, Marc Debouverie, Hélène Zephir, Sandra Vukusic, Gilles Defer

Eur J Neurol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LymphoTEC: a Retrospective Real-World Study on Lymphocyte Reconstitution After Lymphopenia in Patients with Multiple Sclerosis Treated with Dimethyl Fumarate in France.
Jérôme de Sèze, Pierre Labauge, Roland Liblau, Mikel Martinez, Thibault Moreau, Gilles Defer

Adv Ther· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the Risk of Relapse After In Vitro Fertilization in Women With Multiple Sclerosis.
Marie Mainguy, Romain Casey, Sandra Vukusic, Christine Lebrun-Frenay, Eric Berger, Gilles Defer

Neurol Neuroimmunol Neuroinflamm· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic modalities of deferiprone in Parkinson's disease: SKY and EMBARK studies.
David Devos, Olivier Rascol, Wassilios G Meissner, Alexandra Foubert-Samier, Simon Lewis, Gilles Defer

J Parkinsons Dis· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between education level and disability progression in patients with multiple sclerosis in France.
Mathilde Lefort, Olivier Dejardin, Eric Berger, Jean-Philippe Camdessanché, Jonathan Ciron, Gilles Defer

Mult Scler· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between education level and access to disease-modifying treatment in patients with multiple sclerosis in France.
Mathilde Lefort, Olivier Dejardin, Eric Berger, Jean-Philippe Camdessanché, Jonathan Ciron, Gilles Defer

Mult Scler· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis.
John F Foley, Gilles Defer, Lana Zhovtis Ryerson, Jeffrey A Cohen, Douglas L Arnold

Neurol Neuroimmunol Neuroinflamm· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri) Dosing: NOVA Phase IIIb Extension Study (Part 2).
Heinz Wiendl, John Foley, Gilles Defer, Lana Zhovtis Ryerson, Jeffrey A Cohen

Neurol Ther· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-CD20 Therapies in Drug-Naive Patients With Primary Progressive Multiple Sclerosis: A Multicenter Real-Life Study.
Marion Hay, Fabien Rollot, Romain Casey, Anne Kerbrat, Gilles Edan, Gilles Defer

Neurology· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis.
Antoine Gavoille, Fabien Rollot, Romain Casey, Anne Kerbrat, Emmanuelle Le Page, Gilles Defer

JAMA Neurol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society.
Nicolas Collongues, Françoise Durand-Dubief, Christine Lebrun-Frenay, Bertrand Audoin, Xavier Ayrignac, Gilles Defer

Mult Scler· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS.
Guillaume Jouvenot, Guilhem Courbon, Mathilde Lefort, Fabien Rollot, Romain Casey, Gilles Defer

JAMA Neurol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis.
Nail Benallegue, Fabien Rollot, Sandrine Wiertlewski, Romain Casey, Marc Debouverie, Gilles Defer

JAMA Neurol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis.
Pierre Clavelou, Giovanni Castelnovo, Valérie Pourcher, Jerome De Sèze, Patrick Vermersch, Gilles Defer

Neurol Ther· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of 2 Methods for Estimating Multiple Sclerosis-Related Mortality.
Fabien Rollot, Zoé Uhry, Emmanuelle Dantony, Sandra Vukusic, Marc Debouverie, Gilles Defer

Neurology· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis.
Pierre Clavelou, Giovanni Castelnovo, Valérie Pourcher, Jerome De Sèze, Patrick Vermersch, Gilles Defer

Neurol Ther· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert Consensus.
Jerome De Sèze, Laurent Suchet, Claude Mekies, Eric Manchon, Pierre Labauge, Gilles Defer

Neurol Ther· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort.
Juliette Pelle, Anais R Briant, Pierre Branger, Nathalie Derache, Charlotte Arnaud, Gilles Defer

Neurol Ther· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis.
Lana Zhovtis Ryerson, John F Foley, Gilles Defer, Jeffrey A Cohen, Douglas L Arnold

Mult Scler Relat Disord· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference.
Antoine Gavoille, Fabien Rollot, Romain Casey, Marc Debouverie, Emmanuelle Le Page, Gilles Defer

Neurology· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis